News

American Stock Exchange Accepts Callisto Pharamceuticals’ Plan of Compliance and Extension to Regain Compliance with Standards

NEW YORK, Aug. 29, 2007 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL – News; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases,  today announced that the staff of the American Stock Exchange (“AMEX”) has reviewed the Company’s plan of compliance to meet the AMEX’s continued…

Callisto Reports on Second-Quarter 2007 Milestones

NEW YORK, August 8 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, is pleased to provide  an update covering its strategic and drug development activities for the second quarter of 2007. “Callisto has made substantial progress with our clinical and…

Callisto Pharmaceuticals Raises $11.2 Million in Series B Preferred Stock Financing

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL – News; FWB: CA4), a biopharmaceutical company primarily focused on the development of  new drugs to treat cancer and gastrointestinal diseases, announced today that it has closed a private placement of 1,124,550 shares of Series B Convertible Preferred Stock and 22,491,000 warrants for aggregate…

Callisto Pharmaceuticals Announces Patient Dosing in L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia

Multi-Institutional Trial Utilizes POETIC Consortium of Ten Institutions with First Patient Dosed at The Children’s Hospital, Denver CO. NEW YORK, March 8 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the dosing of a patient in a Phase…

Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversion and Related Claims

NEW YORK, June 8 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and inflammatory diseases, announced today that it has filed a complaint against Donald Picker, its former Executive Vice President, Research & Development in the Supreme Court of the State…

Callisto Pharmaceuticals Announces Article Citing Atiprimod in Major Scientific News Journal

History of Atiprimod Appears in Genetic Engineering & Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and inflammatory diseases, announced today that an article citing the history of its anti-cancer drug Atiprimod appeared in Genetic…

Categories